-
Nature Major findings: lower affinity agonist antibody is more effective
Nature重大发现：较低亲和力激动型抗体疗效更优长期以来 ，研究人员将高亲和力作为筛选治疗性抗体的关键标准。目前研究中的激动型抗体多数具有很高的亲和力，并且通过抗体的Fc功能进行交联，从而激活免疫细胞 ，但是这些抗体在临床中的疗效甚微 ，或具有较强的免疫不良反应 。近日，Nature期刊上发表了题为“Reducing affinity as a strategy to boost immunomodul
2023/03/02 admin 48
-
Phase I clinical trial project of YK012 for injection was officially launched
After seven years of sharpening, the phase I clinical trial of YK012 for injection was officially launched recently.YK012 for injection is a new generation of safe, high-yield, long-acting and low-c
2023/02/07 admin 120
-
The 2022 year-end summary meeting ended successfully
On January 18, 2023, the 2022 year-end summary meeting of Ecotech (Beijing) Pharmaceutical Technology Development Co., Ltd. was held in the A101 conference room. All members of the company and the cha
2023/01/10 admin 41
-
The leaders went to the Sino-Science Life Science Industrial Park for investigation
In the afternoon of November 17, Meng Qingwu, Chairman of Yikester (Beijing) Pharmaceutical Technology Development Co., Ltd., and Qian Min, Chief Operating Officer, led a delegation to visit the Zhong
2022/11/10 admin 36
-
Fight against COVID-19 - EXCYTE is in action
"Great Xia, for the country and the people". In 2022, the epidemic was still raging. In response to the call, Yikester, Fan Shuang, Li Meiling and Wei Kun, three comrades, took the initiat
2022/01/10 admin 39
-
The application for YK012 IND, the innovative double antibody of Yikester, was approved and will enter the phase I clinical trial stage
Recently, the bispecific antibody YK012 (acceptance number: CXSL2200041) independently developed by Yikester (Beijing) Pharmaceutical Technology Development Co., Ltd. was officially approved by the Dr
2021/11/10 admin 119
